HOME >> BIOLOGY >> NEWS
New use for a cell toxin found to inhibit survival proteins in cancer cells

to look at how the proteins interact with everything else in the cell. By over expressing this protein, the cell is changed in some interesting ways. It creates a situation where the cell becomes dependent upon the protein, he said. Cancers can become addicted to certain proteins, so just by over expressing the protein the cell changes so that it cant live without that protein.

The next step in this research is to use the assays his lab developed to cast a wider net to find additional compounds that have similar properties to 2-Methoxy antimycin, Hockenbery said. This strategy has already yielded one additional Bcl-xL inhibitor with "gain of function" activity, reported in the Molecular Cancer Therapeutics paper. Funding for the study, 2-Methoxy antimycin reveals a unique mechanism for Bcl-xL inhibition, came from the New Technology Development Fund administered by the Hutchinson Center. Additional key investigators in Hockenberys lab included Michael Manion, Ph.D., and Pam Schwartz, Ph.D., and John Fry.


'"/>

Contact: Dean Forbes
dforbes@fhcrc.org
206-667-2896
Fred Hutchinson Cancer Research Center
11-Jul-2007


Page: 1 2

Related biology news :

1. Children of smokers have more than 5 times higher levels of a nicotine toxin
2. Genome of Clostridium botulinum reveals the background to worlds deadliest toxin
3. Engineered protein effective against Staphylococcus aureus toxin
4. Anthrax paralyzes immune cells with lethal toxin, UF research shows
5. Gene that governs toxin production in deadly mold found
6. Bacterial response to oxidation studied as toxin barometer
7. Scripps research scientists: Compounds show significant promise against potential bioweapon toxins
8. Sea creatures toxin could lead to promising cancer treatment
9. Algae toxin identification unravels fish-kill mystery
10. Red tide toxins leave beachgoers breathless
11. Study reveals molecular basis of botulism toxins deadly activity

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New use for cell toxin found inhibit survival proteins cancer cells

(Date:7/21/2015)... , July 21, 2015 Today, ZTE ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... FPC1 02 5 for Axon , ...
(Date:7/13/2015)... , July 13, 2015 Synaptics ... of human interface solutions, today announced sampling of ... and display driver integration (TDDI) product targeting smartphones ... first to combine Synaptics , best-in-class touch ... display driver technology developed in the company,s Japan ...
(Date:7/9/2015)...  Unchained Labs just can,t get enough biologics ... Nano. Avid Nano designs, develops and manufactures highly ... Also today, Unchained Labs UNcaged the pUNk, ... protein sizing system. The pUNk is a high-performance ... size distribution, aggregation population and molecular weight. Its ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
(Date:7/28/2015)... ... ... VetStem Biopharma will be offering weekly private guided tours of our new ... The tour and course will be given every Wednesday at 6pm to local interested ... members are welcome to attend with their veterinarian as well. Participants will be able ...
(Date:7/28/2015)... 28, 2015 Tauriga Sciences, Inc. (OTCQB:  TAUG) ... company, today announced that its stockholders approved an increase ... of the Company from 1,000,000,000 to 2,500,000,000 at its ... at the Law Offices of Nixon Peabody LLP in ... there were 480,655,929 shares of common stock represented either ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix ... Phase 1 clinical trial with MMI-0100, a first-in-class ... being developed for pulmonary disorders characterized by inflammation ... United Kingdom , is a double-blind, ... evaluating the safety and tolerability of MMI-0100 when ...
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
Breaking Biology Technology:VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
Cached News: